JAK Monotherapy Shows Efficacy in RA Review

A systematic review found Janus kinase inhibitor monotherapy improved outcomes vs methotrexate or placebo, but direct comparisons with combination therapy were limited.

By
Andrea Surnit
May 22, 2026
4 min

Conexiant

At a Glance

Category	Detail
Condition
Key Mechanisms	Janus kinase inhibitors (JAKi) are associated with improved clinical, functional, and radiographic outcomes.
Target Population
Care Setting

Key Highlights

Remove unsupported phrases and ensure all claims are directly sourced.

Guideline-Based Recommendations

Diagnosis

Management

Combination therapy with conventional synthetic DMARDs is generally favored, but monotherapy is allowed for patients who cannot tolerate methotrexate.

Monitoring & Follow-up

Risks

Patient & Prescribing Data

JAKi monotherapy is reported as effective and generally well-tolerated, but safety concerns should be considered.

Clinical Best Practices

Conduct individualized assessments for treatment options.
Evaluate patient history for cardiovascular risks before initiating JAKi therapy.
Ensure regular follow-up to monitor treatment response and adverse events.